Drug Trial Radar · NCT05211830
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Dec 7, 2021
Primary completion
Jun 10, 2025
Study completion Aug 20, 2025
Sponsor
- Lead sponsor
- Sixera PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.
Conditions
- Netherton Syndrome
Interventions
SXR1096 creamDrug
Skin cream to be applied twice a day to a predefined area of the skin
Placebo creamDrug
Skin cream to be applied twice a day to a predefined area of the skin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of the treatment with SXR1096 compared to placebo in initial cohort of adultsTime frame: 4 week
- Safety of the treatment with SXR1096 compared to placebo in adults and adolescentsTime frame: 4 weeks
- Efficacy of the treatment with SXR1096 compared to placebo in adults and adolescentsTime frame: 4 weeks
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Medical University Innsbruck, Tirol Kliniken
Innsbruck, Austria
Saint Louis Hospital
Paris, France
Necker Hospital
Paris, France
University of Freiburg
Freiburg im Breisgau, Germany
Karolinska Hospital, Huddinge
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.